Drug Shortage Report for TABRECTA
| Report ID | 259074 |
| Drug Identification Number | 02527391 |
| Brand name | TABRECTA |
| Common or Proper name | TABRECTA FCT 150MG (10X12) |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | CAPMATINIB |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 10 X 12 |
| ATC code | L01EX |
| ATC description | |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2025-05-27 |
| Actual start date | |
| Estimated end date | 2027-06-27 |
| Actual end date | 2025-07-14 |
| Shortage status | Resolved |
| Updated date | 2025-07-15 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2025-07-15 | English | Compare |
| v6 | 2025-07-14 | French | Compare |
| v5 | 2025-07-14 | English | Compare |
| v4 | 2025-06-02 | French | Compare |
| v3 | 2025-06-02 | English | Compare |
| v2 | 2025-06-02 | French | Compare |
| v1 | 2025-06-02 | English | Compare |
Showing 1 to 7 of 7